Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Head and Neck Cancer

  Free Subscription

Articles published in Cancer

Retrieve available abstracts of 122 articles:
HTML format

Single Articles

    June 2022

  1. Erratum to "Remote triage incorporating symptom-based risk stratification for suspected head and neck cancer referrals: A prospective population-based study".
    Cancer. 2022 Jun 24. doi: 10.1002/cncr.34358.

  2. O'BOYLE CJ, Siravegna G, Varmeh S, Queenan N, et al
    Cell-free human papillomavirus DNA kinetics after surgery for human papillomavirus-associated oropharyngeal cancer.
    Cancer. 2022;128:2193-2204.
    PubMed     Abstract available

    May 2022
  3. HUANG SH, Jacinto JCK, O'Sullivan B, Su J, et al
    Clinical presentation and outcome of human papillomavirus-positive nasopharyngeal carcinoma in a North American cohort.
    Cancer. 2022 May 19. doi: 10.1002/cncr.34266.
    PubMed     Abstract available

  4. NELSON TJ, Thompson CA, Zou J, Kumar A, et al
    Validation of NRG Oncology's prognostic nomograms for oropharyngeal cancer in the Veterans Affairs database.
    Cancer. 2022;128:1948-1957.
    PubMed     Abstract available

  5. COWZER D, Janjigian YY
    Top advances in esophageal/gastroesophageal junction cancers in 2021.
    Cancer. 2022;128:1894-1899.

  6. LI Y, Yao F, Jiao Z, Su X, et al
    Cyclin-dependent kinase 5 promotes the growth of tongue squamous cell carcinoma through the microRNA 513c-5p/cell division cycle 25B pathway and is associated with a poor prognosis.
    Cancer. 2022;128:1775-1786.
    PubMed     Abstract available

    April 2022
  7. KIYOTA N, Tahara M, Robinson B, Schlumberger M, et al
    Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial.
    Cancer. 2022 Apr 5. doi: 10.1002/cncr.34181.
    PubMed     Abstract available

  8. HUTCHESON KA, Barbon CEA, Alvarez CP, Warneke CL, et al
    Refining measurement of swallowing safety in the Dynamic Imaging Grade of Swallowing Toxicity (DIGEST) criteria: Validation of DIGEST version 2.
    Cancer. 2022;128:1458-1466.
    PubMed     Abstract available

    March 2022
  9. PARK S, Oh D, Choi YL, Chi SA, et al
    Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
    Cancer. 2022 Mar 23. doi: 10.1002/cncr.34176.
    PubMed     Abstract available

  10. SOO J, Jin MC, Beadle BM, Holsinger FC, et al
    Circulating tumor DNA in head and neck cancer: Early successes and future promise.
    Cancer. 2022 Mar 17. doi: 10.1002/cncr.34189.
    PubMed     Abstract available

  11. CHUNG HC, Kang YK, Chen Z, Bai Y, et al
    Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients.
    Cancer. 2022;128:995-1003.
    PubMed     Abstract available

    February 2022
  12. EKANAYAKE WEERAMANGE C, Shu D, Tang KD, Batra J, et al
    Analysis of human leukocyte antigen associations in human papillomavirus-positive and -negative head and neck cancer: Comparison with cervical cancer.
    Cancer. 2022 Feb 17. doi: 10.1002/cncr.34148.
    PubMed     Abstract available

  13. OLIVER JR, Persky MJ, Wang B, Duvvuri U, et al
    Transoral robotic surgery adoption and safety in treatment of oropharyngeal cancers.
    Cancer. 2022;128:685-696.
    PubMed     Abstract available

  14. SCOTT-WITTENBORN N, D'Souza G, Tewari S, Rooper L, et al
    Prevalence of human papillomavirus in head and neck cancers at tertiary care centers in the United States over time.
    Cancer. 2022 Feb 8. doi: 10.1002/cncr.34124.
    PubMed     Abstract available

  15. SOUSA LG, Wang K, Torman D, Binks BJ, et al
    Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified.
    Cancer. 2022;128:509-518.
    PubMed     Abstract available

    January 2022
  16. BALACHANDRA S, Eary RL, Lee R, Wynings EM, et al
    Substance use and mental health burden in head and neck and other cancer survivors: A National Health Interview Survey analysis.
    Cancer. 2022;128:112-121.
    PubMed     Abstract available

    December 2021
  17. LIANG L, Liu Z, Zhu H, Wang H, et al
    Efficacy and safety of thalidomide in preventing oral mucositis in patients with nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy: A multicenter, open-label, randomized controlled trial.
    Cancer. 2021 Dec 15. doi: 10.1002/cncr.34074.
    PubMed     Abstract available

  18. WOTMAN MT, Miles BA, Bakst RL, Posner MR, et al
    A proposal for risk-based and strategy-adapted de-escalation in human papillomavirus-positive oropharyngeal squamous cell carcinoma.
    Cancer. 2021;127:4330-4338.

  19. AGGARWAL P, Hutcheson KA, Garden AS, Mott FE, et al
    Determinants of patient-reported xerostomia among long-term oropharyngeal cancer survivors.
    Cancer. 2021;127:4470-4480.
    PubMed     Abstract available

    October 2021
  20. TREISTER NS, Brennan MT, Sollecito TP, Schmidt BL, et al
    Exposed bone in patients with head and neck cancer treated with radiation therapy: An analysis of the Observational Study of Dental Outcomes in Head and Neck Cancer Patients (OraRad).
    Cancer. 2021 Oct 19. doi: 10.1002/cncr.33948.
    PubMed     Abstract available

  21. REN J, Pang W, Hueniken K, Haddad G, et al
    Longitudinal health utility and symptom-toxicity trajectories in patients with head and neck cancers.
    Cancer. 2021 Oct 1. doi: 10.1002/cncr.33936.
    PubMed     Abstract available

  22. FAKHRY C, Tewari SR, Zhang L, Windon MJ, et al
    RTOG-0129 risk groups are reproducible in a prospective multicenter heterogeneously treated cohort.
    Cancer. 2021;127:3523-3530.
    PubMed     Abstract available

    September 2021
  23. FOSTER CC, Couey MA, Kochanny SE, Khattri A, et al
    Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors.
    Cancer. 2021 Sep 21. doi: 10.1002/cncr.33780.
    PubMed     Abstract available

    Reply to Neoadjuvant chemotherapy for locoregionally advanced squamous cell carcinoma of the paranasal sinuses-Is it worthwhile?
    Cancer. 2021;127:3265.

  25. PANDA S, Raveendran S, Kumar R, Thakar A, et al
    Neoadjuvant chemotherapy for locoregionally advanced squamous cell carcinoma of the paranasal sinuses-Is it worthwhile?
    Cancer. 2021;127:3264.

  26. WU J, Xiao F, Zheng Y, Lin Y, et al
    Worldwide trend in human papillomavirus-attributable cancer incidence rates between 1990 and 2012 and Bayesian projection to 2030.
    Cancer. 2021;127:3172-3182.
    PubMed     Abstract available

  27. RYAN WR, Xu MJ, Ochoa E, Plonowska-Hirschfeld KA, et al
    Oncologic outcomes of human papillomavirus-associated oropharynx carcinoma treated with surgery alone: A 12-institution study of 344 patients.
    Cancer. 2021;127:3092-3106.
    PubMed     Abstract available

  28. ABDELMEGUID AS, Silver NL, Boonsripitayanon M, Glisson BS, et al
    Role of induction chemotherapy for oral cavity squamous cell carcinoma.
    Cancer. 2021;127:3107-3112.
    PubMed     Abstract available

    August 2021
  29. SEAMAN AT, Seligman KL, Nguyen KK, Al-Qurayshi Z, et al
    Characterizing head and neck cancer survivors' discontinuation of survivorship care.
    Cancer. 2021 Aug 30. doi: 10.1002/cncr.33888.
    PubMed     Abstract available

  30. HARDMAN JC, Tikka T, Paleri V
    Remote triage incorporating symptom-based risk stratification for suspected head and neck cancer referrals: A prospective population-based study.
    Cancer. 2021 Aug 19. doi: 10.1002/cncr.33800.
    PubMed     Abstract available

  31. GUO TW, Saiyed F, Yao CMKL, Kiong KL, et al
    Outcomes of patients with oropharyngeal squamous cell carcinoma treated with induction chemotherapy followed by concurrent chemoradiation compared with those treated with concurrent chemoradiation.
    Cancer. 2021;127:2916-2925.
    PubMed     Abstract available

  32. CHERA BS, Sheth SH, Patel SA, Goldin D, et al
    Phase 1 trial of adavosertib (AZD1775) in combination with concurrent radiation and cisplatin for intermediate-risk and high-risk head and neck squamous cell carcinoma.
    Cancer. 2021 Aug 11. doi: 10.1002/cncr.33789.
    PubMed     Abstract available

  33. AMIT M, Liu C, Mansour J, Gleber-Netto FO, et al
    Elective neck dissection versus observation in patients with head and neck cutaneous squamous cell carcinoma.
    Cancer. 2021 Aug 6. doi: 10.1002/cncr.33773.
    PubMed     Abstract available

  34. SCHRANK TP, Lenze N, Landess LP, Hoyle A, et al
    Genomic heterogeneity and copy number variant burden are associated with poor recurrence-free survival and 11q loss in human papillomavirus-positive squamous cell carcinoma of the oropharynx.
    Cancer. 2021;127:2788-2800.
    PubMed     Abstract available

    July 2021
  35. YU KJ, Hsu WL, Chiang CJ, Chen TC, et al
    Cancer patterns in nasopharyngeal carcinoma multiplex families over 15 years.
    Cancer. 2021 Jul 29. doi: 10.1002/cncr.33799.
    PubMed     Abstract available

  36. ROMESSER PB, Sherman EJ, Whiting K, Ho ML, et al
    Intensity-modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial.
    Cancer. 2021 Jul 22. doi: 10.1002/cncr.33804.
    PubMed     Abstract available

  37. VAN DIJK LV, Mohamed ASR, Ferrarotto R, McCoy LA, et al
    The impact of induction and/or concurrent chemoradiotherapy on acute and late patient-reported symptoms in oropharyngeal cancer: Application of a mixed-model analysis of a prospective observational cohort registry.
    Cancer. 2021;127:2453-2464.
    PubMed     Abstract available

  38. WHITMARSH A, Pring M, Thomas SJ, Waylen A, et al
    Survival advantage in patients with human papillomavirus-driven oropharyngeal cancer and variation by demographic characteristics and serologic response: Findings from Head and Neck 5000.
    Cancer. 2021;127:2442-2452.
    PubMed     Abstract available

  39. XIAO Q, Kitahara CM
    Reply to associations between light at night and risk of thyroid cancer.
    Cancer. 2021 Jul 10. doi: 10.1002/cncr.33685.

  40. XIAO P, Li L, Ding S, Xie J, et al
    Associations between light at night and risk of thyroid cancer.
    Cancer. 2021 Jul 10. doi: 10.1002/cncr.33686.

  41. LIU Z, Li H, Yu KJ, Xie SH, et al
    Comparison of new magnetic resonance imaging grading system with conventional endoscopy for the early detection of nasopharyngeal carcinoma.
    Cancer. 2021 Jul 7. doi: 10.1002/cncr.33552.
    PubMed     Abstract available

    June 2021
  42. FU TS, Scheffler P, Forner D, Noel CW, et al
    A cost-utility analysis comparing CT surveillance, PET-CT surveillance, and planned postradiation neck dissection for advanced nodal HPV-positive oropharyngeal cancer.
    Cancer. 2021 Jun 1. doi: 10.1002/cncr.33653.
    PubMed     Abstract available

  43. SABA NF
    Preoperative chemotherapy for sinonasal squamous cell carcinoma (SNSCC): Time to move closer to a definitive answer.
    Cancer. 2021;127:1734-1735.

  44. ABDELMEGUID AS, Teeramatwanich W, Roberts DB, Amit M, et al
    Neoadjuvant chemotherapy for locoregionally advanced squamous cell carcinoma of the paranasal sinuses.
    Cancer. 2021;127:1788-1795.
    PubMed     Abstract available

    May 2021
  45. RUAN X, Liang JH, Pan Y, Cai R, et al
    Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single-arm, prospective phase 2 study.
    Cancer. 2021 May 27. doi: 10.1002/cncr.33626.
    PubMed     Abstract available

  46. XIAO C, Beitler JJ, Peng G, Levine ME, et al
    Epigenetic age acceleration, fatigue, and inflammation in patients undergoing radiation therapy for head and neck cancer: A longitudinal study.
    Cancer. 2021 May 24. doi: 10.1002/cncr.33641.
    PubMed     Abstract available

  47. JUNG YS, Seok J, Hong S, Ryu CH, et al
    The emergence of oral cavity cancer and the stabilization of oropharyngeal cancer: Recent contrasting epidemics in the South Korean population.
    Cancer. 2021;127:1638-1647.
    PubMed     Abstract available

  48. SHANMUGAM A, Hariharan AK, Hasina R, Nair JR, et al
    Ultrasensitive detection of tumor-specific mutations in saliva of patients with oral cavity squamous cell carcinoma.
    Cancer. 2021;127:1576-1589.
    PubMed     Abstract available

  49. WEISS JM
    Surgery alone for transorally resected human papillomavirus-driven head and neck cancer-Can we de-intensify adjuvant therapy to 0 Gy and 0 mg/m(2) ?
    Cancer. 2021 May 6. doi: 10.1002/cncr.33610.
    PubMed     Abstract available

    April 2021
  50. DAHLSTROM KR, Song J, Thall PF, Fuller CD, et al
    Conditional survival among patients with oropharyngeal cancer treated with radiation therapy and alive without recurrence 5 years after diagnosis.
    Cancer. 2021;127:1228-1237.
    PubMed     Abstract available

  51. CHEN Y, Chang ET, Liu Q, Cai Y, et al
    Occupational exposures and risk of nasopharyngeal carcinoma in a high-risk area: A population-based case-control study.
    Cancer. 2021 Apr 6. doi: 10.1002/cncr.33536.
    PubMed     Abstract available

    Racial disparity in head and neck cancer.
    Cancer. 2021 Apr 2. doi: 10.1002/cncr.33555.

  53. VOORA RS, Kotha NV, Kumar A, Qiao EM, et al
    Association of Race and Health Care System With Disease Stage and Survival in Veterans With Larynx Cancer.
    Cancer. 2021 Apr 2. doi: 10.1002/cncr.33557.
    PubMed     Abstract available

  54. DRAKE VE, Fakhry C, Windon MJ, Stewart CM, et al
    Timing, number, and type of sexual partners associated with risk of oropharyngeal cancer.
    Cancer. 2021;127:1029-1038.
    PubMed     Abstract available

    March 2021
  55. BALACHANDRA S, Kusin SB, Lee R, Blackwell JM, et al
    Blood-based biomarkers of human papillomavirus-associated cancers: A systematic review and meta-analysis.
    Cancer. 2021;127:850-864.
    PubMed     Abstract available

    February 2021
  56. DE BREE R, de Keizer B
    Comparison of different diagnostic approaches in the management of the clinically negative neck in early oral cancer patients.
    Cancer. 2021 Feb 26. doi: 10.1002/cncr.33443.

  57. NOEL CW, Forner D, Goldstein DP, Metser U, et al
    Elective neck dissection versus positron emission tomography-computed tomography-guided management of the neck in clinically node-negative early oral cavity cancer: A cost-utility analysis.
    Cancer. 2021 Feb 26. doi: 10.1002/cncr.33446.
    PubMed     Abstract available

  58. KIONG KL, Yao CMKL, Lin FY, Bell D, et al
    Delay to surgery after neoadjuvant chemotherapy in head and neck squamous cell carcinoma affects oncologic outcomes.
    Cancer. 2021 Feb 25. doi: 10.1002/cncr.33471.
    PubMed     Abstract available

  59. SHEWALE JB, Pickard RKL, Xiao W, Jiang B, et al
    Independent association of marijuana use and poor oral hygiene with HPV-negative but not HPV-positive head and neck squamous cell carcinomas.
    Cancer. 2021 Feb 23. doi: 10.1002/cncr.33440.
    PubMed     Abstract available

  60. WANG SM, Freedman ND, Katki HA, Matthews C, et al
    Gastroesophageal reflux disease: A risk factor for laryngeal squamous cell carcinoma and esophageal squamous cell carcinoma in the NIH-AARP Diet and Health Study cohort.
    Cancer. 2021 Feb 22. doi: 10.1002/cncr.33427.
    PubMed     Abstract available

    Head and neck cancer staging: Balancing innovation with consistency.
    Cancer. 2021 Feb 17. doi: 10.1002/cncr.33415.

  62. HO AS, Luu M, Kim S, Tighiouart M, et al
    Nodal staging convergence for HPV- and HPV+ oropharyngeal carcinoma.
    Cancer. 2021 Feb 17. doi: 10.1002/cncr.33414.
    PubMed     Abstract available

  63. PRINTZ C
    Study adds evidence to link between gum disease and cancer risk: Researchers observe connection with gastric, esophageal cancer.
    Cancer. 2021;127:495-496.

  64. CAMPBELL BR, Chen Z, Faden DL, Agrawal N, et al
    The mutational landscape of early- and typical-onset oral tongue squamous cell carcinoma.
    Cancer. 2021;127:544-553.
    PubMed     Abstract available

  65. ZHANG D, Jones RR, James P, Kitahara CM, et al
    Associations between artificial light at night and risk for thyroid cancer: A large US cohort study.
    Cancer. 2021 Feb 8. doi: 10.1002/cncr.33392.
    PubMed     Abstract available

  66. YIP L, Gooding WE, Nikitski A, Wald AI, et al
    Risk assessment for distant metastasis in differentiated thyroid cancer using molecular profiling: A matched case-control study.
    Cancer. 2021 Feb 4. doi: 10.1002/cncr.33421.
    PubMed     Abstract available

  67. STRACHNA O, Cohen MA, Allison MM, Pfister DG, et al
    Case study of the integration of electronic patient-reported outcomes as standard of care in a head and neck oncology practice: Obstacles and opportunities.
    Cancer. 2021;127:359-371.
    PubMed     Abstract available

    January 2021
  68. YAO CMKL, Fu S, Tam S, Kiong KL, et al
    Impact of provider type and number of providers on surveillance testing among survivors of head and neck cancers.
    Cancer. 2021 Jan 20. doi: 10.1002/cncr.33402.
    PubMed     Abstract available

  69. ALHUMAIDI H, Manochakian R, Cochuyt J, Chindris A, et al
    Initial treatment of patients with thyroid cancer: Outcomes and factors associated with care at academic versus nonacademic cancer centers.
    Cancer. 2021 Jan 15. doi: 10.1002/cncr.33408.
    PubMed     Abstract available

  70. LIN YT, Wang HC, Tsai MH, Su YY, et al
    Angiotensin II receptor blockers valsartan and losartan improve survival rate clinically and suppress tumor growth via apoptosis related to PI3K/AKT signaling in nasopharyngeal carcinoma.
    Cancer. 2021 Jan 6. doi: 10.1002/cncr.33391.
    PubMed     Abstract available

    December 2020

  71. Head and neck cancer surgery during the COVID-19 pandemic: An international, multicenter, observational cohort study.
    Cancer. 2020 Dec 21. doi: 10.1002/cncr.33320.
    PubMed     Abstract available

  72. AMIT M, Liu C, Gleber-Netto FO, Kini S, et al
    Inclusion of extranodal extension in the lymph node classification of cutaneous squamous cell carcinoma of the head and neck.
    Cancer. 2020 Dec 15. doi: 10.1002/cncr.33373.
    PubMed     Abstract available

    November 2020
  73. KAWASAKI M, Ikeda Y, Ikeda E, Takahashi M, et al
    Oral infectious bacteria in dental plaque and saliva as risk factors in patients with esophageal cancer.
    Cancer. 2020 Nov 6. doi: 10.1002/cncr.33316.
    PubMed     Abstract available

    October 2020
  74. MORGAN RL, Eguchi MM, McDermott J, Mueller AC, et al
    Comparative effectiveness of posttreatment imaging modalities for Medicare patients with advanced head and neck cancer.
    Cancer. 2020 Oct 29. doi: 10.1002/cncr.33244.
    PubMed     Abstract available

  75. LIU W, Qdaisat A, Ferrarotto R, Fuller CD, et al
    Hypomagnesemia and survival in patients with head and neck cancers who received primary concurrent chemoradiation.
    Cancer. 2020 Oct 21. doi: 10.1002/cncr.33283.
    PubMed     Abstract available

  76. SWIECICKI PL, Bellile EL, Brummel CV, Brenner JC, et al
    Efficacy of axitinib in metastatic head and neck cancer with novel radiographic response criteria.
    Cancer. 2020 Oct 20. doi: 10.1002/cncr.33226.
    PubMed     Abstract available

  77. ZHANG N, Li Y, Chang X, Lei F, et al
    Long-term effectiveness of one-time endoscopic screening for esophageal cancer: A community-based study in rural China.
    Cancer. 2020;126:4511-4520.
    PubMed     Abstract available

  78. ZAKERI K, Rotolo F, Lacas B, Vitzthum LK, et al
    Predictive classifier for intensive treatment of head and neck cancer.
    Cancer. 2020 Oct 5. doi: 10.1002/cncr.33212.
    PubMed     Abstract available

    September 2020
  79. G V REDDY N, Singh A, Subash A
    Preservation of spinal accessory and level 2b-sparing neck dissection: The balance beyond oncology and functionality.
    Cancer. 2020 Sep 17. doi: 10.1002/cncr.33166.

    Reply to Preservation of spinal accessory and level 2b-sparing neck dissection: The balance beyond oncology and functionality.
    Cancer. 2020 Sep 17. doi: 10.1002/cncr.33164.

  81. HU J, Huang Q, Gao J, Guan X, et al
    Clinical outcomes of carbon-ion radiotherapy for patients with locoregionally recurrent nasopharyngeal carcinoma.
    Cancer. 2020 Sep 15. doi: 10.1002/cncr.33197.
    PubMed     Abstract available

  82. REYES-GIBBY CC, Wang J, Zhang L, Peterson CB, et al
    Oral microbiome and onset of oral mucositis in patients with squamous cell carcinoma of the head and neck.
    Cancer. 2020 Sep 5. doi: 10.1002/cncr.33161.
    PubMed     Abstract available

    August 2020
  83. DE ALMEIDA JR, Noel CW, Forner D, Zhang H, et al
    Development and validation of a surgical prioritization and ranking tool and navigation aid for head and neck cancer (SPARTAN-HN) in a scarce resource setting: Response to the COVID-19 pandemic.
    Cancer. 2020 Aug 11. doi: 10.1002/cncr.33114.
    PubMed     Abstract available

  84. HONG MH, Heo SG, Lee YG, Kim HS, et al
    Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma.
    Cancer. 2020 Aug 4. doi: 10.1002/cncr.33123.
    PubMed     Abstract available

    July 2020
  85. KIONG KL, Lin FY, Yao CMKL, Guo T, et al
    Impact of neoadjuvant chemotherapy on perioperative morbidity after major surgery for head and neck cancer.
    Cancer. 2020 Jul 24. doi: 10.1002/cncr.33103.
    PubMed     Abstract available

  86. SAITO Y, Hayashi R, Iida Y, Mizumachi T, et al
    Optimization of therapeutic strategy for p16-positive oropharyngeal squamous cell carcinoma: Multi-institutional observational study based on the national head and neck cancer registry of Japan.
    Cancer. 2020 Jul 10. doi: 10.1002/cncr.33062.
    PubMed     Abstract available

  87. KANG JJ, Wong RJ, Sherman EJ, Rybkin A, et al
    The 3 B's of cancer care amid the COVID-19 pandemic crisis: "Be safe, be smart, be kind"-A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancer.
    Cancer. 2020 Jul 8. doi: 10.1002/cncr.33031.
    PubMed     Abstract available

  88. SCHUTTE HW, van den Broek GB, Steens SCA, Hermens RPMG, et al
    Impact of optimizing diagnostic workup and reducing the time to treatment in head and neck cancer.
    Cancer. 2020 Jul 7. doi: 10.1002/cncr.33037.
    PubMed     Abstract available

    June 2020
  89. HUENIKEN K, Douglas CM, Jethwa AR, Mirshams M, et al
    Measuring financial toxicity incurred after treatment of head and neck cancer: Development and validation of the Financial Index of Toxicity questionnaire.
    Cancer. 2020 Jun 30. doi: 10.1002/cncr.33032.
    PubMed     Abstract available

  90. BROUGHMAN JR, Xiong DD, Moeller BJ, Contrera KJ, et al
    Rethinking the 10-pack-year rule for favorable human papillomavirus-associated oropharynx carcinoma: A multi-institution analysis.
    Cancer. 2020;126:2784-2790.
    PubMed     Abstract available

  91. LEE AWM, Ngan RKC, Ng WT, Tung SY, et al
    NPC-0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma.
    Cancer. 2020 Jun 4. doi: 10.1002/cncr.32972.
    PubMed     Abstract available

  92. CAVALIERI S, Licitra L
    Induction chemotherapy is the best timekeeper in nasopharyngeal carcinoma.
    Cancer. 2020 Jun 4. doi: 10.1002/cncr.32971.

  93. HUANG SH, O'Sullivan B, Su J, Ringash J, et al
    Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal.
    Cancer. 2020 Jun 1. doi: 10.1002/cncr.32968.
    PubMed     Abstract available

  94. LANG KUHS KA, Wood CB, Wiggleton J, Aulino JM, et al
    Transcervical sonography and human papillomavirus 16 E6 antibodies are sensitive for the detection of oropharyngeal cancer.
    Cancer. 2020;126:2658-2665.
    PubMed     Abstract available

    May 2020
  95. MIMICA X, McGill M, Hay A, Karassawa Zanoni D, et al
    Distant metastasis of salivary gland cancer: Incidence, management, and outcomes.
    Cancer. 2020;126:2153-2162.
    PubMed     Abstract available

  96. SEIWERT TY, Kochanny S, Wood K, Worden FP, et al
    A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study.
    Cancer. 2020 May 4. doi: 10.1002/cncr.32929.
    PubMed     Abstract available

    April 2020
  97. PRINTZ C
    Radiation from computed tomography scans is associated with increased risk for thyroid cancer and leukemia.
    Cancer. 2020;126:1601.

  98. BIGELOW EO, Blackford AL, Eytan DF, Eisele DW, et al
    Burden of comorbidities is higher among elderly survivors of oropharyngeal cancer compared with controls.
    Cancer. 2020;126:1793-1803.
    PubMed     Abstract available

  99. FULLERTON ZH, Butler SS, Mahal BA, Muralidhar V, et al
    Short-term mortality risks among patients with oropharynx cancer by human papillomavirus status.
    Cancer. 2020;126:1424-1433.
    PubMed     Abstract available

  100. OLIVER JR, Lieberman SM, Tam MM, Liu CZ, et al
    Human papillomavirus and survival of patients with sinonasal squamous cell carcinoma.
    Cancer. 2020;126:1413-1423.
    PubMed     Abstract available

  101. HERMANN GM, Iovoli AJ, Platek AJ, Wang C, et al
    A single-institution, randomized, pilot study evaluating the efficacy of gabapentin and methadone for patients undergoing chemoradiation for head and neck squamous cell cancer.
    Cancer. 2020;126:1480-1491.
    PubMed     Abstract available

    March 2020
  102. ZHAN KY, Puram SV, Li MM, Silverman DA, et al
    National treatment trends in human papillomavirus-positive oropharyngeal squamous cell carcinoma.
    Cancer. 2020;126:1295-1305.
    PubMed     Abstract available

  103. VALERO C, Zanoni DK, McGill MR, Ganly I, et al
    Pretreatment peripheral blood leukocytes are independent predictors of survival in oral cavity cancer.
    Cancer. 2020;126:994-1003.
    PubMed     Abstract available

    January 2020
  104. GULATI S, Desai J, Palackdharry SM, Morris JC, et al
    Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer.
    Cancer. 2020;126:354-362.
    PubMed     Abstract available

  105. TIAN S, Jiang R, Madden NA, Ferris MJ, et al
    Survival outcomes in patients with gastric and gastroesophageal junction adenocarcinomas treated with perioperative chemotherapy with or without preoperative radiotherapy.
    Cancer. 2020;126:37-45.
    PubMed     Abstract available

  106. FREITAG J, Wald T, Kuhnt T, Gradistanac T, et al
    Extracapsular extension of neck nodes and absence of human papillomavirus 16-DNA are predictors of impaired survival in p16-positive oropharyngeal squamous cell carcinoma.
    Cancer. 2020;126:1856-1872.
    PubMed     Abstract available

  107. RODEN DF, Hobelmann K, Vimawala S, Richa T, et al
    Evaluating the impact of smoking on disease-specific survival outcomes in patients with human papillomavirus-associated oropharyngeal cancer treated with transoral robotic surgery.
    Cancer. 2020;126:1873-1887.
    PubMed     Abstract available

  108. XIAO Q, Li Z, Ji J
    Patients with gastroesophageal junction adenocarcinomas of an advanced stage may benefit from perioperative chemoradiotherapy: A validation based on the Surveillance, Epidemiology, and End Results database.
    Cancer. 2020;126:2036-2037.

  109. FAN M, Kang JJ, Lee A, Fan D, et al
    Outcomes and toxicities of definitive radiotherapy and reirradiation using 3-dimensional conformal or intensity-modulated (pencil beam) proton therapy for patients with nasal cavity and paranasal sinus malignancies.
    Cancer. 2020;126:1905-1916.
    PubMed     Abstract available

  110. LOCATI LD, Galbiati D, Calareso G, Alfieri S, et al
    Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life.
    Cancer. 2020;126:1888-1894.
    PubMed     Abstract available

    December 2019
  111. CHEN DW, Reyes-Gastelum D, Wallner LP, Papaleontiou M, et al
    Disparities in risk perception of thyroid cancer recurrence and death.
    Cancer. 2019 Dec 23. doi: 10.1002/cncr.32670.
    PubMed     Abstract available

    October 2019
  112. FAN D, Ma J, Bell AC, Groen AH, et al
    Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer.
    Cancer. 2019 Oct 8. doi: 10.1002/cncr.32548.
    PubMed     Abstract available

  113. PRINTZ C
    First person profile: Albert de la Chapelle, MD, PhD: Known for several pioneering discoveries in genetics, Dr. de la Chapelle is working to shed light on the genes that cause thyroid cancer.
    Cancer. 2019;125:3285-3286.

    September 2019
  114. YOSHIDA EJ, Luu M, Mallen-St Clair J, Mita AC, et al
    Stage I HPV-positive oropharyngeal cancer: Should all patients receive similar treatments?
    Cancer. 2019 Sep 19. doi: 10.1002/cncr.32501.
    PubMed     Abstract available

    July 2019
  115. BERNIER MO, Kitahara CM, Shiels MS
    Reply to Natural history of thyroid cancer suggests beginning of the overdiagnosis of juvenile thyroid cancer in the United States and Harm of overdiagnosis or extremely early diagnosis behind trends in pediatric thyroid cancer.
    Cancer. 2019 Jul 29. doi: 10.1002/cncr.32425.

  116. MIDORIKAWA S, Murakami M, Ohtsuru A
    Harm of overdiagnosis or extremely early diagnosis behind trends in pediatric thyroid cancer.
    Cancer. 2019 Jul 29. doi: 10.1002/cncr.32426.

  117. TAKANO T
    Natural history of thyroid cancer suggests beginning of the overdiagnosis of juvenile thyroid cancer in the United States.
    Cancer. 2019 Jul 29. doi: 10.1002/cncr.32424.

    June 2019
  118. SHERMAN EJ, Dunn LA, Schoder H, Ho AL, et al
    Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer.
    Cancer. 2019 Jun 7. doi: 10.1002/cncr.32046.
    PubMed     Abstract available

    April 2019
  119. ROLLO F, Pichi B, Benevolo M, Giuliani M, et al
    Oral testing for high-risk human papillomavirus DNA and E6/E7 messenger RNA in healthy individuals at risk for oral infection.
    Cancer. 2019 Apr 29. doi: 10.1002/cncr.32152.
    PubMed     Abstract available

    We cannot ignore the real component of the rise in thyroid cancer incidence.
    Cancer. 2019 Apr 23. doi: 10.1002/cncr.32123.

  121. CHEN AY, Davies L
    Children and thyroid cancer: Interpreting troubling trends.
    Cancer. 2019 Apr 23. doi: 10.1002/cncr.32124.

  122. BERNIER MO, Withrow DR, Berrington de Gonzalez A, Lam CJK, et al
    Trends in pediatric thyroid cancer incidence in the United States, 1998-2013.
    Cancer. 2019 Apr 23. doi: 10.1002/cncr.32125.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.